Authors relationships and activities IL has received research funding (paid to the institution they are affiliated with) from Boehringer Ingelheim, Merck, Mylan, Novo Nordisk, Pfizer and Sanofi, and has received advisory/consulting fees and/or other support from AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GI Dynamics, Intarcia Therapeutics, Intercept Pharmaceuticals, Johnson & Johnson, MannKind, Merck, Mylan, Novartis, Novo Nordisk, Pfizer, Sanofi, Shionogi, Structure Therapeutics, Target Pharma, Valeritas and Zealand Pharma
In practice, many obesity specialists have found themselves deviating from the label slowing down titration, adding intermediate doses, maintaining lower doses longer, or skipping weeks to help patients stay on therapy
S2CID 43716740
Get Thin MD provides a range of weight loss medications, including GLP-1 options like Liraglutide, with a strong focus on patient satisfaction and individualized care
The benefits of an ALCAR supplement over an L-carnitine product relates to its bioavailability
See our semaglutide guide